Hattori K, Tamura M, Ono M
Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan.
In Vivo. 1996 May-Jun;10(3):361-8.
To examine the effect of human granulocyte colony-stimulating factor (G-CSF) on the hemopoietic response to repeated treatment with the anticancer drug cyclophosphamide (CPA) in mice, we determined the optimal time interval between CPA doses which was required to equalize the recovery of neutrophils in the first and second cycle. G-CSF-treatment significantly shortened the optimal time interval of CPA doses when compared with treatment with the control vehicle. The studies on resistance to a second CPA cycle and hemopoietic parameters indicated that the resistance correlated positively with the granulocyte colony-forming cel (G-CFC) population in marrow, in both control and G-CSF-treated mice. In G-CSF-treated mice, moreover, the resistance correlated positively with the ratio of G-CFC in proliferative state and negatively correlated with the neutrophil levels in peripheral blood. These results suggest that G-CSF shortens the optimal time interval between CPA doses not only by accelerating the recovery of G-CFC but also by affecting the hemopoietic environment.
为了研究人粒细胞集落刺激因子（G-CSF）对小鼠反复使用抗癌药物环磷酰胺（CPA）后造血反应的影响，我们确定了在第一个和第二个周期中使中性粒细胞恢复相等所需的CPA剂量之间的最佳时间间隔。与用对照载体治疗相比，G-CSF治疗显著缩短了CPA剂量的最佳时间间隔。对第二个CPA周期的抗性和造血参数的研究表明，在对照小鼠和G-CSF治疗的小鼠中，抗性与骨髓中的粒细胞集落形成细胞（G-CFC）群体呈正相关。此外，在G-CSF治疗的小鼠中，抗性与增殖状态下的G-CFC比例呈正相关，与外周血中的中性粒细胞水平呈负相关。这些结果表明，G-CSF不仅通过加速G-CFC的恢复，而且通过影响造血环境来缩短CPA剂量之间的最佳时间间隔。
